有機化學人才網 | 最新人才 | 最新職位 | 技術交易 | 藥物合成 |
   
全站搜索: |
  您當前位置:網站首頁 >> 藥物合成路線圖解
 

藥物詳細合成路線

Name Tirofiban hydrochloride;MK-383;L-700462;Aggrastat
Chemical Name N-(Butylsulfonyl)-4-O-[4-(4-piperidyl)butyl]-L-tyrosine monohydrochloride
CAS 142373-60-2
Related CAS 144494-65-5 (free base), 150915-40-5 (monoH2O)
Formula C22H37ClN2O5S
Structure
Formula Weight 477.06759
Stage 上市-1998
Company Merck & Co. (Originator), Banyu (Licensee), Guilford Pharmaceuticals (Licensee)
Activity/Mechanism Acute Myocardial Infarction, Treatment of, Angina pectoris, Treatment of, Antiplatelet Therapy, CARDIOVASCULAR DRUGS, Cerebrovascular Diseases, Treatment of, Coagulation Disorders Therapy, HEMATOLOGIC DRUGS, NEUROLOGIC DRUGS, Stroke, Treatment of, Treatment of Disorders of the Coronary Arteries and Atherosclerosis, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists
Syn. Route 6
Route 1
4-pyridineacetic acid (i) was hydrogenated to the corresponding piperidine (ii) in the presence of pto2. after protection of (ii) as the n-boc derivative (iii), reduction of its carboxylate group with borane in thf provided alcohol (iv). subsequent swern oxidation of alcohol (iv) furnished aldehyde (v). this was then subjected to a wittig condensation with carbomethoxytriphenylphosphorane to yield the unsaturated ester (vi), which was further hydrogenated to (vii) in the presence of pd/c. after saponification of the methyl ester function of (vii), the resultant carboxylic acid was reduced to alcohol (viii) by means of borane in thf. conversion of alcohol (viii) into the alkyl bromide (ix) was accomplished by treatment with carbon tetrabromide and triphenylphosphine. then, alkylation of the phenolic hydroxyl of n-cbz-l-tyrosine (x) with bromide (ix) in the presence of nah in dmf afforded adduct (xi).
List of intermediates No.
methyl (1s,4s,6r,10r)-15-oxo-5-oxatetracyclo[8.4.1.0(1,6).0(4,6)]pentadec-7-ene-8-carboxylate (i)
(2r)-3-[[tert-butyl(dimethyl)silyl]oxy]-2-(dibenzylamino)-1-propanol (iii)
(x)
methyl (e)-3-[4-(acetyloxy)phenyl]-2-propenoate (iv)
(4s,7s,13r,16r,22r)-13-ethyl-4-(1h-indol-3-ylmethyl)-7-[(4-methoxy-1h-indol-3-yl)methyl]-18,22-dimethyl-16-[(phenylseleninyl)methyl]-24-thia-3,6,9,12,15,18,21,26-octaazabicyclo[21.2.1]hexacosa-1(25),23(26)-diene-2,5,8,11,14,17,20-heptone (ii)
4,8-dimethyl-7-hydroxycoumarin (vi)
4,8-dimethyl-7-(1-methyl-2-oxopropoxy)-2h-chromen-2-one (vii)
Reference 1:
    egbertson, m.s.; laswell, w.l.; hartman, g.d.; duggan, m.e.; halczenko, w. (merck & co., inc.); novel sulfonamide fibrinogen receptor antagonists. ep 0478363; ep 0743302; jp 1992288051; us 5292756 .
Reference 2:
    egbertson, m.s.; hartman, g.d.; halczenko, w.; laswell, w.l.; duggan, m.e. (merck & co., inc.); novel sulfonamide fibrinogen receptor antagonists. wo 9319046 .
Reference 3:
    egbertson, m.s.; chang, c.t.c.; duggan, m.e.; et al.; non-peptide fibrinogen receptor antagonists. 2. optimization of a tyrosine template as a mimic for arg-gly-asp. j med chem 1994, 37, 16, 2537.

Route 2
acid (xi) was converted to the methyl ester (xii) by alkylation with iodomethane in the presence of cs2co3. after removal of the n-cbz group of (xii) by catalytic hydrogenolysis, the resultant amine (xiii) was acylated by butanesulfonyl chloride (xiv) producing sulfonamide (xv). saponification of the ester group of (xv) with lioh gave acid (xvi). the n-boc group of (xvi) was finally cleaved by treatment with hcl in etoac.
List of intermediates No.
2-[(4s)-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl]acetic acid (xiv)
Reference 1:
    egbertson, m.s.; hartman, g.d.; halczenko, w.; laswell, w.l.; duggan, m.e. (merck & co., inc.); novel sulfonamide fibrinogen receptor antagonists. wo 9319046 .
Reference 2:
    egbertson, m.s.; laswell, w.l.; hartman, g.d.; duggan, m.e.; halczenko, w. (merck & co., inc.); novel sulfonamide fibrinogen receptor antagonists. ep 0478363; ep 0743302; jp 1992288051; us 5292756 .
Reference 3:
    egbertson, m.s.; chang, c.t.c.; duggan, m.e.; et al.; non-peptide fibrinogen receptor antagonists. 2. optimization of a tyrosine template as a mimic for arg-gly-asp. j med chem 1994, 37, 16, 2537.

Route 3
intermediate (xi) was converted to the title compound by an alternative method, reported to provide a higher enantiomeric excess. hydrogenolysis of the n-cbz group of (xi) in the presence of pd/c gave the aminoacid (xv). subsequent acylation of (xv) with butanesulfonyl chloride (xiv) under schotten-baumann conditions furnished sulfonamide (xvi), which was then treated with hcl in etoac to remove the n-boc protecting group.
List of intermediates No.
2-[(4s)-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl]acetic acid (xiv)
Reference 1:
    egbertson, m.s.; chang, c.t.c.; duggan, m.e.; et al.; non-peptide fibrinogen receptor antagonists. 2. optimization of a tyrosine template as a mimic for arg-gly-asp. j med chem 1994, 37, 16, 2537.

Route 4
in a different strategy, the lithium derivative of 4-picoline (xvii) was alkylated with 2-(3-bromopropoxy)tetrahydropyran (xviii) to afford (xix). acidic hydrolysis of the tetrahydropyranyl protecting group furnished 4-(4-pyridinyl)butanol (xx). alternatively, lithiation of 4-picoline (xvii), followed by alkylation with 1-bromo-3-chloropropane (xxi) gave rise to 4-(4-pyridinyl)butyl chloride (xxii).
List of intermediates No.
ethyl 2-(3,4-dimethoxyphenyl)-3-[[2-(3,4-dimethoxyphenyl)acetyl]amino]propanoate (xxi)
ethyl (e)-3-[(3ar,6r,6ar)-2,2,6-trimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl]-4-(benzyloxy)-2-butenoate (xvii)
tert-butyl 2-(benzylamino)acetate (xviii)
Reference 1:
    chung, j.y.l.; zhao, d.; hughes, d.l. (merck & co., inc.); process for preparing fibrinogen receptor antagonists. us 5312923; wo 9316994 .
Reference 2:
    chung, j.y.l.; zhao, d.; hughes, d.l. (merck & co., inc.); process for preparing fibrinogen receptor antagonists. wo 9316995 .
Reference 3:
    chung, j.y.l.; zhao, d.; hughes, d.l.; grabowski, e.e.; a practical synthesis of fibrinogen receptor antagonist mk-383 - selective functionalization of (s)-tyrosine. tetrahedron 1993, 49, 26, 5767.

Route 5
tyrosine methyl ester (xxiii) was acylated with butanesulfonyl chloride (xiv) in the presence of pyridine to produce sulfonamide (xxiv). mitsunobu coupling of pyridinyl butanol (xx) with the phenolic compound (xxiv) furnished ether (xxv). subsequent hydrolysis of the methyl ester group of (xxv) employing lioh afforded acid (xxvi). the title piperidine compound was then obtained by catalytic hydrogenation of the pyridine ring of (xxvi) in the presence of pd/c.
List of intermediates No.
disodium 4-amino-4-[[4,6-bis(3-[[bis(3-amino-3-oxopropyl)amino]sulfonyl]anilino)-1,3,5-triazin-2-yl]amino][1,1-biphenyl]-2,2-disulfonate (xxiii)
2-[(4s)-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl]acetic acid (xiv)
Reference 1:
    chung, j.y.l.; zhao, d.; hughes, d.l. (merck & co., inc.); process for preparing fibrinogen receptor antagonists. us 5312923; wo 9316994 .

Route 6
in a variation of this process, l-tyrosine (xxvii) was initially protected as the bis-o-silylated derivative (xxviii) employing n,o-bis(trimethylsilyl) trifluoroacetamide. acylation of (xxviii) with butanesulfonyl chloride (xiv), followed by hydrolysis of the silyl groups, gave rise to n-butanesulfonyl tyrosine (xxix). the phenolic hydroxyl of (xxix) was then alkylated by 4-(4-pyridinyl)butyl chloride (xxii) to produce ether (xxvi). finally, hydrogenation of the pyridine ring furnished the target piperidine derivative, which was isolated as the corresponding hydrochloride salt.
List of intermediates No.
2-[(4s)-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl]acetic acid (xiv)
2-hydroxy-6-pentadecylbenzoic acid (xxvii)
Reference 1:
    chung, j.y.l.; zhao, d.; hughes, d.l. (merck & co., inc.); process for preparing fibrinogen receptor antagonists. wo 9316995 .
Reference 2:
    chung, j.y.l.; zhao, d.; hughes, d.l.; grabowski, e.e.; a practical synthesis of fibrinogen receptor antagonist mk-383 - selective functionalization of (s)-tyrosine. tetrahedron 1993, 49, 26, 5767.

來源:藥化網

作者:藥化小編

摘要:本文合成路線介紹的是藥物中文名鹽酸替羅非班;英文名Tirofiban hydrochloride;MK-383;L-700462;Aggrastat;CAS[142373-60-2]

 
推薦VIP企業
無錫景耀生物科技有限公司
杭州盧普生物科技有限公司
寧波賽倫化工有限公司
蘇州昊賽生物科技有限公司
北京嘉盛揚醫藥科技有限公司
上海澤涵生物醫藥科技有限公司
河北固安三利化工公司
鄭州凱普瑞生物技術有限公司
上海藥谷藥業有限公司
蘭州康寓信生物科技有限公司
湖北朗昕生化藥業有限公司
武漢福鑫化工有限公司
嘉興市英南化工有限公司
蘇州迪飛醫藥科技有限公司
唐山盛源澤興化工有限公司
上海盛中醫藥化工有限公司
連云港天和化學有限公司
南京晨瑞醫藥科技有限公司
南京蘇如化工有限公司
常州瑞盛化工有限公司
熱門文章
農業農村部種植業管理司:這10
紅太陽全球首家擁有敵草快二氯鹽
解讀:新化學物質環境管理登記辦
先正達在意大利推出殺蟲劑Min
國際農藥分析協作委員會的農藥與
近期我國農藥制造業十大規模項目
主打植物生長調節劑和水溶性肥的
拉美非法農藥貿易有增無減,各國
“禾本綠色農藥研究院”被認定為
先正達以行動助力可持續農業!“
堅決禁止不必要環保執法! 違規
先正達將在阿根廷分銷Rizob
拜耳作物科學事業部2020一季
透過穎泰生物2019年報看行業
Amoeba與拜耳簽署關于生物
開發“專利到期”農藥,也要重視
巴西對252種已登記的制劑產品
解讀:中華人民共和國農業農村部
當今現代物理農業的四個高端技術
疫情下,農藥出口貿易公司如何突
 友情鏈接
有機化學人才網  
首頁 | 廣告服務 | 建站服務 | 關于我們 | 聯系我們 | 版權聲明
怎样才能在直播中赚钱 内蒙古快3开奖走势图 江西时时彩单双 甘肃11选5一定牛 168开奖现场直播结果+开奖结果 广东麻将真钱 广东好彩1肖开奖 pk10长期稳赚6码 广东十一选五官方网站 吉林11选5玩法技巧 网络投资理财平台哪个好